Olivia Vizier

At age 50, Alexandria Forbes founded MeiraGTx, a gene therapy company with six clinical programs and innovative technology to control genes with pills. (Gene-based medicine is typically administered via the injection of cells through a vector.)

Recce Pharmaceuticals, a biotechnology company focused on the global antibiotic-resistant patient population. This new class of synthetic antibiotics takes a broad-spectrum approach to kill bacterial infections, which continue to mutate, rendering existing antibiotics ineffective. The founding inventor of Recce is Dr. Graham Melrose, the grandfather of James, who has grown this idea into one of

Philipp Spycher has an extensive background in bioconjugation and ADCs. He obtained his master’s degree and Ph.D. from ETH Zurich in material science and protein engineering. During his post-doctoral work at Paul Scherrer Institute, he introduced the novel approach of using transglutaminases for antibody conjugation, which led to the discovery of what is now called

Meanwhile, Aphaia Pharma is also developing a promising drug candidate for weight loss, APH-012, with a focus on why L-cells – nutrient-sensing cells in the distal part of the intestine – in patients with metabolic disease are largely deprived from contact with food, as this leads to a lack of endocrine, neuroendocrine, and neuronal stim

Ambrx is the pioneer of an expanded genetic code technology platform for synthetic amino acid incorporation into proteins at any position, providing a unique

Xalud is using a non-viral DNA plasmid vector to restore homeostasis and treat pathologic inflammation within the immune system. Howard Rutman, M.D., MBA, Chief Medical Officer at Xalud Therapeutics

Switzerland-based Aphaia Pharma, in May launched its Phase II clinical trial of its daily glucose formulation, which is taken mixed with water. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed.

Tessera Therapeutics–a biotechnology startup based in Somerville, Massachusetts–followed with more modest flair: a simple banner, a speaker, and about 30 team members.

In MindMed’s LSD trial in Fort Collins, some groups are excluded from participation: pregnant women and people with a history of psychosis. That’s because the risks of using psychedelics in these populations are not fully understood.

The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders.

A different approach, pursued by Zug, Switzerland-based Aphaia Pharma, is to reawaken nutrient-sensing cells in the distal gut that become less responsive in obesity

Elicio Therapeutics on Thursday said it closed a previously announced reverse merger

Reata is a biotech stock with a perfect Relative Strength Rating of 99, putting its 12-month price performance in the top 1% of all stocks, according to IBD Digital.

At the inception of eFFECTOR, one of the key considerations was that, to extend the duration of benefit of a given treatment, you have to contend with resistance. It had become clear that, even when using the most tightly targeted therapy or immunotherapy, resistance happens. I’ve spent about 15 years in the antiviral world working

Umoja wants to offer a solution. The biotech is working on ways to confront all the major limitations of CAR T-cell therapy—the lengthy, pricey manufacturing process and the poor efficacy against solid tumors—with therapies that reengineer a patient’s T cell

Since Dan O’Connor stepped in as CEO at Ambrx late last year, the company’s stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O’Connor is no stranger to overcoming adversity.

When I hosted Immunome President & CEO Purnanand Sarma, Ph.D. on episode 104 of the Business of Biotech podcast last summer, the company, like many emerging biotechs, was still wrapped up in rationalizing an application for its antibody technology in the battle against COVID-19.

Swiss biopharma startup Aphaia Pharma AG is taking the concept of “location, location, location” to its extreme. The company started dosing patients in a phase II trial of its lead candidate, Aph-012, in late April, 2023. The trial is a randomized, double-blind, placebo-controlled, multicenter proof-of-concept study to evaluate Aph-012’s ability to improve glucose tolerance in

Araris Biotech is using this linker technology to develop next-generation ADCs with the potential to be safer and more efficacious for cancer patients. In head-to-head animal model studies against FDA approved ADCs, the ADCs created using Araris’ linker technology demonstrated improved efficacy, even at low doses, as well as high tolerability.

Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, they were the first vectors that were developed for gene therapy delivery. A plethora of viral vectors entered the gene therapy arena including lentiviruses, retroviruses, herpes simplex viruses, adenoviruses and adeno-associated viruses. Each of these vector

Tumor-infiltrating myeloid cells such as tumor-associated macrophages (TAMs) can suppress T-cell recruitment and function and promote the expansion and dissemination of cancer cells depending on their functional states. In hepatocellular carcinoma (HCC), TAMs are associated with resistance to sorafenib, the first-line treatment for advanced HCC.

Later this year, Umoja Biopharma will open 77,000 square feet of a 146,000 square foot manufacturing facility at the Colorado Technology Center in Louisville. Although Umoja is only in the early clinical stage of developing CAR-T therapeutics, the company got an early start on creating a facility to make the lentiviral vectors that it will

Life Biosciences, a biotech advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury, has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.

Revolo Biotherapeutics’ ‘1104 is designed to reset the immune system “upstream” before the inflammatory cascade occurs.

Ikena has seen no proteinuria in monkey trials, and Manfredi reckons others are now following his company in developing subtype-selective Tead inhibitors to get around toxicity; Sporos’s Tead1/4 inhibitor SPRI-0117 appears to be one of these.

Revolo Biotherapeutics thinks it has the data to keep advancing a would-be challenger to Dupixent. In a small, short phase 2a allergy trial, the biotech linked its peptide to a “numeric reduction” on the primary endpoint, emboldening it to start looking forward to further development.

Our lead anti-infective candidate, RECCE® 327 (R327), will be advancing into a Phase Ia/IIb intravenous multiple ascending dose safety and tolerability study and a Phase II clinical trial investigating the efficacy of R327 against diabetic foot ulcer (DFU) infections.

Life Biosciences’ gene therapy platform works by inducing expression of the transcription factors Oct3/4, Sox2 and Klfr4, or OSK—three of the four Yamanaka factors. When all four Yamanaka factors are expressed together, have been shown to fully reprogram differentiated human, mouse and primate cells back into pluripotent stem cells, erasing their cell identity and resetting

Shares of MindMed surged Friday morning after researchers who have worked with the company unveiled positive results in a trial using LSD to treat major depressive disorder, running a test similar to the biotech’s trials of its own related compound.

As a ‘smart knee’ that transmits data rolls out, medical specialists and engineers predict sensors will be added to artificial hips, shoulders and spinal implants.